BACKGROUND: CYP2D6 is an important cytochrome P450 enzyme. These enzymes catalyse the oxidative biotransformation of about 25% of clinically important drugs as well as the metabolism of numerous environmental chemical carcinogens. The most frequent null allele of CYP2D6 in European populations, CYP2D6*4, has been studied here in order to elucidate whether a relationship exists between this allele and the risk of developing breast cancer in a Spanish population. MATERIALS AND METHODS: Ninety-six breast cancer Spanish patients and one hundred healthy female volunteers were genotyped for the CYP2D6*4 allele using AmpliChip CYP450 Test technology. RESULTS: Homozygous CYP2D6*4 frequency was significant lower in breast cancer patients than in the control group (OR=0.22, p=0.04). The heterozygous CYP2D6*4 group also displayed lower values in patients than in controls but the difference was not significant (OR=0.698, p=0.28). Therefore, the presence of the CYP2D6*4 allele seems to decrease susceptibility to breast carcinoma in the selected population. CONCLUSIONS: A possible decreased transformation of procarcinogens by CYP2D6*4 poor metabolisers could result in a protective effect against carcinogens.
BACKGROUND:CYP2D6 is an important cytochrome P450 enzyme. These enzymes catalyse the oxidative biotransformation of about 25% of clinically important drugs as well as the metabolism of numerous environmental chemical carcinogens. The most frequent null allele of CYP2D6 in European populations, CYP2D6*4, has been studied here in order to elucidate whether a relationship exists between this allele and the risk of developing breast cancer in a Spanish population. MATERIALS AND METHODS: Ninety-six breast cancer Spanish patients and one hundred healthy female volunteers were genotyped for the CYP2D6*4 allele using AmpliChip CYP450 Test technology. RESULTS: Homozygous CYP2D6*4 frequency was significant lower in breast cancerpatients than in the control group (OR=0.22, p=0.04). The heterozygous CYP2D6*4 group also displayed lower values in patients than in controls but the difference was not significant (OR=0.698, p=0.28). Therefore, the presence of the CYP2D6*4 allele seems to decrease susceptibility to breast carcinoma in the selected population. CONCLUSIONS: A possible decreased transformation of procarcinogens by CYP2D6*4 poor metabolisers could result in a protective effect against carcinogens.
Authors: Priya Chacko; Thomas Joseph; Beela Sarah Mathew; Balakrishnan Rajan; M Radhakrishna Pillai Journal: Mutat Res Date: 2005-01-18 Impact factor: 2.433
Authors: R C Strange; T Ellison; F Ichii-Jones; J Bath; P Hoban; J T Lear; A G Smith; P E Hutchinson; J Osborne; B Bowers; P W Jones; A A Fryer Journal: Pharmacogenetics Date: 1999-06
Authors: Leonor Gomes; Manuel C Lemos; Isabel Paiva; Cristina Ribeiro; Manuela Carvalheiro; Fernando J Regateiro Journal: Acta Med Port Date: 2005-10-16
Authors: Sarah C Preissner; Michael F Hoffmann; Robert Preissner; Mathias Dunkel; Andreas Gewiess; Saskia Preissner Journal: PLoS One Date: 2013-12-10 Impact factor: 3.240
Authors: Ana Fernández-Santander; María Gaibar; Apolonia Novillo; Alicia Romero-Lorca; Margarita Rubio; Luis Miguel Chicharro; Armando Tejerina; Fernando Bandrés Journal: PLoS One Date: 2013-07-29 Impact factor: 3.240